ACTRN12620000844943撤回3 期
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; C-SMART studyArm 4: Effect of Lenzilumab in cancer patients with severe COVID-19 infection.
Peter MacCallum Cancer Centre0 个研究点目标入组 72 人开始时间: 2020年8月26日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Age equal to or greater than 18 years of age.
- •2. Any haematological or solid tumour
- •3. Current or within the last 12 months received cancer related treatment such as chemotherapy, radiotherapy or targeted small molecule, cellular therapy or immune-modulating therapy
- •4. Signed written and verbal informed consent by participant or proxy capable of giving consent
- •5. Laboratory virological confirmation of SARS-CoV-2 by PCR as per local laboratory assays and COVID-19 diagnosis prior to randomisation
- •6. Hospitalised but has not required mechanical ventilation
- •7. Pneumonia diagnosed by chest x-ray or computed tomography (CT) revealing infiltrates consistent with pneumonia and SpO2 equal to or less than 94% on room air or requires low-flow oxygen supplementation or requires high-flow oxygen supplementation or non-invasive positive pressure ventilation (NIPPV).
- •8. Has not participated in other clinical trials for COVID-19 using an immunomodulating monoclonal antibody or kinase inhibitor. Note that participants on dexamethasone, corticosteroids, remdesivir, convalescent plasma and/or hydroxychloroquine with or without azithromycin are not excluded from the study. Agents that have received emergency use authorization and/or are considered by the study site to be standard treatment at the institution for COVID-19 are permitted provided the agent is not an immunomodulating monoclonal antibody or kinase inhibitor. Participation in clinical trials with remdesivir or convalescent plasma is permitted provided that all other eligibility criteria are met.
- •9. Females of childbearing potential must have a negative serum or urine pregnancy test at screening/baseline. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for 5 months following their last dose of study drug.
排除标准
- •1. Invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
- •2. History of pulmonary alveolar proteinosis (PAP).
- •3. Women of childbearing potential who are pregnant or breastfeeding.
- •4. Known hypersensitivity to lenzilumab or any of its components.
- •5 .Use of any FDA-approved anti-IL-6 therapy (eg. tocilizumab, sarilumab, siltukimab), anti-IL-1 therapy (eg. anakinra, canakinumab) or kinase inhibitor (eg.baracitinib, ibrutinib, acalabrutinib) therapy to treat COVID-19 within 8 weeks prior to randomization. Any live vaccine within 8 weeks prior to randomisation. Note that subjects receiving other FDA-approved immunomodulators to treat underlying autoimmune disorders such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, atopic dermatitis, multiple sclerosis, etc. would not be excluded. Participants on corticosteroids or dexamethasone are not excluded from the study. Note: Participants on convalescent plasma, remdesivir and/or hydroxychloroquine with or without azithromycin are not excluded from the study.
- •6. Use of GM-CSF agents (e.g., sargramostim) within 8 weeks prior to randomisation.
- •7. Expected survival < 24h in the opinion of the investigator.
- •8. Any condition that, in the opinion of the investigator, is likely to interfere with the safety and efficacy of the study treatment or puts the subject at unacceptably high risk from the study.
- •9. Participation in another interventional study of COVID-19
研究者
相似试验
已完成
3 期
C-SMART.COVID-19 Prevention and Treatment in Cancer. Arm 3: treatment among cancer patients with moderate COVID-19 infection.CancerACTRN12620000841976Peter MacCallum Cancer Centre3
已完成
3 期
C-SMART.COVID-19 Prevention and Treatment in Cancer. Arm 1 : Prevention in patients not infected with COVID-19.CancerACTRN12620000843954Peter MacCallum Cancer Centre440
撤回
3 期
C-SMART.COVID-19 Prevention and Treatment in Cancer. Arm 2 : Post-exposure prevention in patients recently exposed to COVID-19CancerACTRN12620000842965Peter MacCallum Cancer Centre170
已完成
不适用
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trialCOVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000557932AProf Dr Karin Ried446
招募中
1 期
Therapies to prevent progression of COVID-19 in outpatients: The 'Primary Care Australian COVID-19 Therapeutics' (PACT) TrialACTRN12622000386730AProf Dr Karin Ried300